Current knowledge regarding Asherson's syndrome

Expert Review of Clinical Immunology

Volumn 5, Issue 5, 2009, Pages 587-591

  De Carvalho, Jozélio F ^a   Pereira, Rosa M R ^a   Shoenfeld, Yehuda ^b,c  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b SHEBA MEDICAL CENTER   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

Antiphospholipid syndrome; Ashersons syndrome; Catastrophic antiphospholipid syndrome; Intravenous immunoglobulin; Plasma exchange; Thrombophilia

Indexed keywords

ANTICOAGULANT AGENT; BETA2 GLYCOPROTEIN 1; GLUCOCORTICOID; HEPARIN; IMMUNOGLOBULIN; PHOSPHOLIPID ANTIBODY;

ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; ENDOTHELIUM CELL; FIBRINOLYSIS; GENETIC RISK; HEPARINIZATION; HUMAN; MOLECULAR MIMICRY; MORTALITY; PATHOPHYSIOLOGY; PLASMAPHERESIS; REVIEW; SURVIVAL; THROMBOSIS;

EID: 77949796460     PISSN: 1744666X     EISSN: None     Source Type: Journal    
DOI: 10.1586/eci.09.34     Document Type: Review

References (36)

1. Asherson RA. The catastrophic antiphospholipid syndrome. J. Rheumatol. 19, 508-512 (1992).
2. Asherson RA, Cervera R, Piette JC et al. Catastrophic antiphospholipid syndrome. Clinical and laboratory features of 50 patients. Medicine (Baltimore) 77, 195-207 (1998).
3. Kitchens CS. Thrombotic storm: when thrombosis begets thrombosis. Am. J. Med. 104, 381-385 (1998).
4. Meroni PL, Raschi E, Camera M et al. Endothelial activation by aPL: a potential pathogenetic mechanism for the clinical manifestations of the syndrome. J. Autoimmun. 15, 237-240 (2000).
5. Raschi E, Testoni C, Bosisio D et al. Role of the MyD88 transduction signaling pathway in endothelial activation by antiphospholipid antibodies. Blood 101, 3495-3500 (2003).
6. Asherson RA, Shoenfeld Y. The role of infection in the pathogenesis of catastrophic antiphospholipid syndrome - molecular mimicry? J. Rheumatol. 27, 12-14 (2000).
7. Gharavi AE, Pierangeli SS. Origin of antiphospholipid antibodies: induction of aPL by viral peptides. Lupus 7, S52-S54 (1998).
8. Sène D, Piette JC, Cacoub P. Antiphospholipid antibodies, antiphospholipid syndrome and infections. Autoimmun. Rev. 7, 272-277 (2008).
9. Ortega-Hernandez OD, Agmon-Levin N, Blank M, Asherson RA, Shoenfeld Y. The physiopathology of the catastrophic antiphospholipid (Ashersons) syndrome: compelling evidence. J. Autoimmun. 32, 1-6 (2009).
10. Ortega-Hernandez OD, Agmon-Levin N, Blank M, Asherson RA, Shoenfeld Y. The pathophysiology of the catastrophic antiphospholipid syndrome: compelling evidence. Clin. Rev. Allergy Immunol. (2008) (Epub ahead of print).
11. Gharavi AE, Pierangeli SS, Colden- Stanfield M et al. GDKV-induced antiphospholipid antibodies enhance thrombosis and activate endothelial cells in vivo and in vitro. J. Immunol. 163, 2922-2927 (1999).
12. Blank M, Shoenfeld Y, Cabilly S, Heldman Y, Fridkin M, Katchalski-Katzir E. Prevention of experimental antiphospholipid syndrome and endothelial cell activation by synthetic peptides. Proc. Natl Acad. Sci. USA 96, 5164-5168 (1999).
13. Gharavi AE, Pierangeli SS, Espinola RG, Liu X, Colden-Stanfield M, Harris EN. Antiphospholipid antibodies induced in mice by immunization with a cytomegalovirus-derived peptide cause thrombosis and activation of endothelial cells in vivo. Arthritis Rheum. 46, 545-552 (2002).
14. Makatsariya A, Asherson RA, Bitsadze V, Baimuradova S, Akinshina S. Catastrophic antiphospholipid (Ashersons) syndrome and genetic thrombophilic disorders in obstetrics. Autoimmun. Rev. 6, 89-93 (2006).
15. Cervera R, Bucciarelli S, Espinosa G et al. Catastrophic antiphospholipid syndrome: lessons from the 'CAPS Registry - a tribute to the late Josep Font. Ann. NY Acad. Sci. 1108, 448-456 (2007).
16. Stojanovich L, Marisavljevic D, Rovensky J, Djokovich A, Kozáková D, Milinic N. Clinical and laboratory features of the catastrophic antiphospholipid syndrome. Clin. Rev. Allergy Immunol. 36, 74-79 (2009).
17. Cervera R, Shoenfeld Y. Microangiopathic antiphospholipid antibody-associated síndromes: a tribute to Ronald Asherson. Isr. Med. Assoc. J. 10, 894-895 (2008).
18. Asherson RA, Cervera R. Microvascular and microangiopathic antiphospholipidassociated síndromes ('MAPS): semántica or antisemantic? Autoimmun. Rev. 7, 164-167 (2008).
19. Cervera R, Font J, Gómez-Puerta JA et al.; Catastrophic antiphospholipid syndrome registry project group. Validation of the preliminary criteria for the classification of catastrophic antiphospholipid syndrome. Ann. Rheum. Dis. 64, 1205-1209 (2005).
20. Asherson RA. The catastrophic antiphospholipid (Ashersons) syndrome. Autoimmun. Rev. 6, 64-67 (2006).
21. Miesbach W, Asherson RA, Cervera R et al. Members of CAPS Registry Group. The catastrophic antiphospholipid (Ashersons) syndrome and malignancies. Autoimmun. Rev. 6, 94-97 (2006).
22. Bucciarelli S, Cervera R, Espinosa G, Gómez-Puerta JA, Ramos-Casals M, Font J. Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors. Autoimmun. Rev. 6, 72-75 (2006).
23. Asherson RA, Cervera R, Piette JC et al. Catastrophic antiphospholipid syndrome: clues to the pathogenesis from a series of 80 patients. Medicine (Baltimore) 80, 355-377 (2001).
24. Orbach H, Katz U, Sherer Y, Shoenfeld Y. Intravenous immunoglobulin: adverse effects and safe administration. Clin. Rev. Allergy Immunol. 29, 173-184 (2005).
25. Amital H, Levy Y, Davidson C et al. Catastrophic antiphospholipid syndrome: remission following leg amputation in 2 cases. Semin. Arthritis Rheum. 31, 127-132 (2001).
26. Rubenstein E, Arkfeld DG, Metyas S, Shinada S, Ehresmann S, Liebman HA. Rituximab treatment for resistant antiphospholipid syndrome. J. Rheumatol. 33, 355-357 (2006).
27. Nageswara Rao AA, Arteaga GM, Reed AM, Gloor JM, Rodriguez V. Rituximab for successful management of probable pediatric catastrophic antiphospholipid syndrome. Pediatr. Blood Cancer. 52, 536-538 (2009).
28. Asherson RA, Espinosa G, Menahem S et al. Relapsing catastrophic antiphospholipid syndrome: report of three cases. Semin. Arthritis Rheum. 37, 366-372 (2008).
29. Bayraktar UD, Erkan D, Bucciarelli S, Espinosa G, Asherson R; Catastrophic Antiphospholipid Syndrome Project Group. The clinical spectrum of catastrophic antiphospholipid syndrome in the absence and presence of lupus. J. Rheumatol. 34, 346-352 (2007).
30. Bucciarelli S, Espinosa G, Cervera R et al.; European Forum on Antiphospholipid Antibodies. Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors in a series of 250 patients. Arthritis Rheum. 54, 2568-2576 (2006).
31. Espinosa G, Bucciarelli S, Asherson RA, Cervera R. Morbidity and mortality in the catastrophic antiphospholipid syndrome: pathophysyology, causes of death, and prognostic factors. Semin. Thromb. Hemost. 34, 290-294 (2008).
32. Erkan D, Asherson RA, Espinosa G et al.; Catastrophic Antiphospholipid Syndrome Registry Project Group. Long term outcome of catastrophic antiphospholipid syndrome survivors. Ann. Rheum. Dis. 62, 530-533 (2003).
33. Undas A, Swadbaź J, Undas R, Musiał J. Three episodes of acute multiorgan failure in a woman with secondary antiphospholipid syndrome. Pol. Arch. Med. Wewn. 100, 556-560 (1998).
34. Cerveny KC, Sawitzke AD. Relapsing catastrophic antiphospholipid antibody syndrome: a mimic for thrombotic thrombocytopenic purpura? Lupus 8, 477-481 (1999).
35. Bucciarelli S, Erkan D, Espinosa G, Cervera R. Catastrophic antiphospholipid syndrome: treatment, prognosis, and the risk of relapse. Clin. Rev. Allergy Immunol. 36, 80-84 (2009).
36. Cheng HM, Chamley L. Cryptic natural autoantibodies and co-potentiators. Autoimmun. Rev. 7, 431-434 (2008).